Skip to content

Multimodal blood management in perioperative total knee arthroplasty: a randomized, double-blind, controlled trial

Multimodal blood management in perioperative total knee arthroplasty: a randomized, double-blind, controlled trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IIR-16008461
Enrollment
Unknown
Registered
2016-05-12
Start date
2015-12-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary osteoarthritis of knee

Interventions

treatment group:Multimodal blood management
control group:standard blood management

Sponsors

Department of Orthopaedics, Xijing Hospital, The Fourth Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: Adult patients who plan to undergo primary TKA on simultaneous bilateral knee joint with a diagnosis of osteoarthritis or aseptic bone necrosis, but not of rheumatoid arthritis

Exclusion criteria

Exclusion criteria: 1. Allergy to tranexamic acid; 2. Receiving warfarin or heparin; had a history of hemophilia, deep venous thrombosis, pulmonary embolism, or renal impairment; or were pregnant; 3. Patients with any cardiovascular problems (such as myocardiac infarction history, atrial fibrillation, angina); 4. Patients with cerebrovascular conditions (such as previous stroke or vascular surgery history); 5. Patients with thromboembolic disorders, or those exhibiting a deteriorating general condition; 6.a history of transfusion in 1 month; 7. Preoperative use of anticoagulant therapy within five days before surgery, coagulopathy.

Design outcomes

Primary

MeasureTime frame
Proportion of patients who were transfused with allogeneic blood;Amounts of allogeneic blood transfused;

Secondary

MeasureTime frame
Average amounts of blood loss;Complications (myocardial infarction, stroke, deep vein thrombosis, pulmonary embolism, any thrombosis, renal failure): CE + DU (Postoperative Day 5);Active range of motion (pre-operation and post-operative Day 5);Decreased Hb;Calculated blood loss;KSS score (at 6th week after surgery);

Countries

China

Contacts

Public ContactZhu Qingsheng

Department of Orthopaedics, Xijing Hospital, The Fourth Military Medical University

zhuqsh@fmmu.edu.cn+86 02984775280

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026